Royal Sense Limited is an emerging Indian healthcare enterprise specializing in the integrated trading, supply, and distribution of medical devices, pharmaceuticals, surgical consumables, and diagnostic solutions. Established in **2023** through the strategic consolidation of three predecessor firms (**Royal Traders**, **PHT**, and **Anaya**), the company has rapidly transitioned from a regional trader to a **PAN India** healthcare provider. Following its successful listing on the **BSE SME** platform in **March 2024**, the company is currently pivoting toward a high-margin retail franchise model and international regulatory compliance. --- ### **Operational Infrastructure & Business Model** Royal Sense operates a trading-intensive model, sourcing high-quality medical products that meet international standards and distributing them through an extensive national network. * **Consolidated Synergy:** The **2023** merger of the promoter’s original firms (dating back to **2015**) was designed to optimize resources and maximize market impact. * **Strategic Facilities:** In **January 2025**, the company transitioned from rented premises to a self-owned **factory-cum-corporate office** in **Badli Industrial Area, Delhi**. This move streamlines warehousing and administrative operations. * **Supply Chain Expansion:** To support scaling, the company secured a **five-year lease** (effective **February 2026**) for a dedicated warehouse in **Sonipat, Haryana**. * **Distribution Channels:** * **Government Sector:** Supplies to the Ministry of Health in **Uttar Pradesh, Himachal Pradesh, Rajasthan, and Jammu & Kashmir** via the **GEM Portal** and state-level tenders. * **Private Sector:** Serves private hospitals, diagnostic centers, and independent practitioners. * **Quick Commerce:** Recently entered distribution agreements with **Zepto** and **Blinkit** to broaden the market footprint for essential health products. --- ### **Diversified Product Portfolio & Brand Strategy** The company markets its products under the registered brand name **"STERGIC"** and maintains a portfolio of over **80+ products** launched in **FY 2024-25**. #### **1. Pharmaceuticals & Nutraceuticals** Focuses on high-strength formulations and advanced delivery systems: * **Vitamin Supplements:** **Cholecalciferol Nano Shot (60,000 IU)** using nano-droplet technology for rapid absorption; **StergiVita** softgels and syrups. * **Antibiotics:** **Steropenam 1gm** (Meropenem), **Nomoceft 1gm** (Ceftriaxone), and **Ugmntin** (Amoxicillin + Clavulanic Acid). * **Ayurvedic/Herbal:** Specialized range including **Liver Shakti DS**, **Stree Shakti**, and **Smriti Shakti**. #### **2. Medical Devices & Surgical Consumables** Royal Sense holds **US FDA approval** (FEI: **3033531399**) for over **40 products**: * **Respiratory Care:** **Stergic Mesh Nebulizer** (vibrating mesh technology) and **Lumia** compressor nebulizers. * **Surgicals:** Sterile sutures, bandages, gauze, and syringes. * **PPE & Hygiene:** Face shields and masks with protective barriers lasting up to **5 hours**. * **Mobility Aids:** Adjustable walkers, crutches, and cervical supports. #### **3. In-Vitro Diagnostics (IVD)** The company provides rapid, lateral flow immunochromatographic assays: * **Infectious Diseases:** Rapid kits for **HIV 1+2, HCV, Syphilis, HBsAg, Typhoid,** and **Chikungunya**. * **Dengue Combo:** The **Stergic Dengue IgG/IgM Rapid Test** (launched **August 2024**) differentiates between recent and past infections. * **Pregnancy:** **Pregaonce** and **Stergic** kits providing results within **2 minutes**. --- ### **Financial Performance & Capital Structure** The company has demonstrated robust growth post-listing, characterized by significant revenue and profit expansion. | Metric | FY 2023-24 | FY 2024-25 | Growth (%) | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | ₹1,899 Lakhs | **₹2,772.29 Lakhs** | **~46%** | | **Profit After Tax (PAT)** | ₹170.19 Lakhs | **₹304.00 Lakhs** | **55.89%** | | **Earnings Per Share (EPS)** | **5.57** (Consolidated) | - | - | **Capital Raising Activities:** * **IPO (April 2024):** Issued **14,50,000** shares at **₹68/share**. * **Warrant Issuance:** * **Tranche I (Nov 2024):** **4,50,000** warrants at **₹151/share**. * **Tranche II (May 2025):** **4,00,000** warrants at **₹251/share**, targeting a raise of **₹10.04 Crore**. * **Current Paid-up Capital:** **₹5,35,01,460** (as of May 2025). * **Authorized Borrowing:** The Board is empowered to borrow up to **₹50 Crore** to fund expansion. --- ### **Strategic Growth Drivers: Retail & M&A** Royal Sense is aggressively pursuing a transition from a pure B2B trader to a B2C retail powerhouse. * **"Stergic Pharmacy" Franchise:** Launched a Franchise Owned Company Operated (**FOCO**) model. The company received over **125 applications** by August 2025, with the flagship counter opening in **Rohini, Delhi** in **February 2026**. * **Merger by Absorption:** The company is in the process of merging with **TTG Innovations Private Limited (TIPL)**. Despite an initial rejection by BSE in April 2025 due to valuation timing, the company received a **"No adverse observations"** letter in **November 2025** following a fresh valuation. * **Sector Diversification:** Amended its Memorandum of Association (MoA) in late 2025 to include the manufacture and trade of **cosmetics, perfumes, and dermatological products**. * **Subsidiaries:** Operates **Stergic Retail Private Limited** as a wholly-owned subsidiary. --- ### **Market Opportunity & Valuation Context** The company targets high-growth healthcare niches in India: * **Nutraceuticals:** Market estimated at **₹50,000–60,000 Crore** (**15–20% CAGR**). * **Liver Care (Hepatoprotective):** Segment valued at **₹2,000–3,500 Crore**, driven by rising NAFLD prevalence. * **Dermatology Creams:** Market estimated at **₹2,500–4,000 Crore**. --- ### **Risk Management & Compliance** Royal Sense manages risks under **Section 134(3)(n)** of the Companies Act, 2013, focusing on the following areas: * **Regulatory & Legal:** Subject to stringent healthcare standards. The company mitigates this through a dedicated quality assurance team and **US FDA/CE** certifications. * **Market Competition:** Faces pressure from unorganized players and low entry barriers. Strategy focuses on **brand reputation** and **exclusive distribution rights**. * **Operational Risks:** Vulnerability to supply chain disruptions and technological obsolescence. The company addresses this by maintaining a **committed customer base** and diversifying into **personalized medicine** and **biosimilars**. * **Financial Solvency:** Statutory auditors have confirmed the company’s ability to meet all liabilities falling due within **one year**.